For the millions of Americans injecting themselves weekly with Wegovy, Ozempic, Mounjaro, or Zepbound, the promise of a simple daily pill that works just as well has felt perpetually out of reach. That changed with the publication of results from a major Phase 3 trial: orforglipron, an experimental oral tablet developed by Eli Lilly, produced up to roughly 12 to 13 percent body weight loss over 72 weeks in adults with obesity or overweight, putting it in the same range as the injectable GLP-1 drugs that have dominated headlines and pharmacy shelves. A second trial showed that patients who switched from those injections to the pill largely held onto the weight they had already lost.
The findings, published in the New England Journal of Medicine in mid-2026, land at a moment when demand for GLP-1 medications far outstrips supply and needle aversion remains one of the most common reasons patients never start or quietly stop treatment.
What the ATTAIN-1 trial actually showed
ATTAIN-1 was a randomized, double-blind, placebo-controlled trial that enrolled adults with a body mass index of 30 or higher (or 27 with at least one weight-related condition) who did not have type 2 diabetes. Participants took one of three daily doses of orforglipron (6 mg, 12 mg, or 36 mg) or a matching placebo for 72 weeks.
All three doses beat placebo by a wide margin. The highest dose, 36 mg, delivered the most dramatic results, with participants losing a placebo-adjusted average in the low-to-mid teens in percentage terms of their starting body weight. Even the lowest dose, 6 mg, produced clinically meaningful reductions. For context, semaglutide 2.4 mg (the active ingredient in Wegovy) produced about 12.4 percent placebo-adjusted weight loss over 68 weeks in its landmark STEP 1 trial, and tirzepatide (Mounjaro and Zepbound) achieved roughly 15 to 21 percent in SURMOUNT-1 depending on dose. Orforglipron’s top dose falls within that corridor, though direct head-to-head trials have not been conducted.
The side-effect profile followed the familiar GLP-1 pattern. Nausea, vomiting, and diarrhea were the most frequently reported adverse events, occurring most often during the dose-escalation phase and tapering over time. Discontinuation rates due to side effects were higher in the drug groups than in placebo, a tradeoff that mirrors what clinicians already see with injectable options.
Switching from injections to a pill
A separate trial called ATTAIN-MAINTAIN tackled a question that patients on Wegovy or Mounjaro are already asking their doctors: could I switch to a pill and keep my results?
Published in Nature Medicine, the Phase 3b study enrolled adults who had been losing weight on injectable semaglutide or tirzepatide and randomly assigned them to either oral orforglipron or placebo for 52 weeks. (Some readers may need to log in through a publisher access page to view the full paper.)
The core finding: participants who switched to orforglipron largely maintained their prior weight loss, while those moved to placebo regained a significant portion. The degree of protection varied by orforglipron dose and by which injectable the patient had been taking, but the overall signal was clear enough to suggest that the pill could serve as a viable maintenance option after injectable therapy, at least over a one-year window.
Beyond weight loss: results in type 2 diabetes
Orforglipron is not being developed solely as an obesity drug. In ACHIEVE-1, a 40-week Phase 3 trial also published in the New England Journal of Medicine, the pill lowered blood sugar levels meaningfully in people with early type 2 diabetes while simultaneously producing weight loss. A related trial, ATTAIN-2, studied the drug in people living with both obesity and type 2 diabetes; those results appeared in The Lancet.
Taken together, the four trials sketch a broad profile: an oral GLP-1 receptor agonist that works across the metabolic spectrum, from obesity without diabetes to established type 2 diabetes with excess weight. That breadth matters because many patients carry both conditions, and a single daily pill addressing both could simplify treatment regimens that currently involve multiple medications.
What orforglipron still has to prove
Promising trial results are not the same as a proven therapy. Several important gaps remain before orforglipron can be considered a true replacement for injectable GLP-1 drugs.
No long-term cardiovascular data. Semaglutide earned a major competitive advantage when the SELECT trial demonstrated that it reduced heart attacks, strokes, and cardiovascular deaths in people with obesity over a median follow-up of roughly 40 months. Orforglipron has nothing comparable. Its longest completed trial ran 72 weeks, far too short to detect cardiovascular outcomes. Regulators and cardiologists will likely want a dedicated outcomes trial before the pill can claim heart-protective benefits.
No direct head-to-head trials against competitors. Cross-trial comparisons suggest orforglipron’s efficacy is in the same neighborhood as semaglutide and tirzepatide, but differences in study populations, baseline weights, and trial designs make precise matchups unreliable. Until a randomized trial directly compares the pill to one or more injectables, the “matches the injections” framing carries an asterisk.
Real-world adherence is unknown. The assumption that a daily pill will keep more patients on treatment than a weekly injection is intuitive but unproven. Clinical trials provide structured support (regular visits, reminders, counseling) that inflates adherence beyond what pharmacies typically see. And daily dosing introduces its own challenge: remembering to take a pill every morning, potentially on an empty stomach, is a different kind of burden than a once-weekly shot. Post-marketing data will be needed to settle the question.
Pricing and insurance coverage remain unclear. Eli Lilly has not disclosed a target price for orforglipron. Injectable GLP-1 drugs currently carry list prices above $1,000 per month in the United States, and insurers have been inconsistent about covering them for obesity. Whether an oral formulation will be priced lower, and whether payers will treat it differently, are open questions with enormous implications for patient access.
FDA approval is not guaranteed. Lilly has signaled its intent to seek regulatory approval, but the timeline and outcome depend on the agency’s review of the full data package, including safety signals across all trials. No approval date has been publicly confirmed as of June 2026.
Why the oral format changes the calculus
Even with those caveats, the significance of a pill that rivals injectable GLP-1 drugs should not be understated. Needle aversion is not a trivial barrier. Surveys of patients eligible for injectable weight-loss medications consistently find that a meaningful share either delay starting treatment or discontinue it because of discomfort with self-injection. An effective oral alternative could expand the eligible population, improve long-term persistence, and reduce the logistical burden of cold-chain shipping and needle disposal that complicates injectable drug distribution.
It also arrives in a competitive context. Novo Nordisk already markets Rybelsus, an oral form of semaglutide approved for type 2 diabetes, but that drug requires strict fasting conditions before each dose and, at its current approved dose, produces less weight loss than the injectable version. Novo Nordisk is testing higher oral semaglutide doses for obesity, and other companies are pursuing their own oral GLP-1 candidates. Orforglipron’s small-molecule design gives it a potential edge: because it is not a peptide, it does not face the same absorption challenges that force oral semaglutide patients to take their pill on an empty stomach with minimal water and then wait 30 minutes before eating.
For patients weighing their options, the practical question is straightforward but not yet answerable: when will this pill be available, how much will it cost, and will my insurance cover it? The clinical data published so far suggest the drug works. The remaining hurdles are regulatory, economic, and logistical, and those will determine whether orforglipron becomes a mainstream treatment or remains a promising trial result waiting for its moment.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
